ArticleCureus2026
Vexas Syndrome Without Macrocytosis: A Case Highlighting an Expanding Clinical Phenotype and Diagnostic Delay.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
VEXAS (Vacuoles, E1 enzyme, X-linked, Autoinflammatory, Somatic) syndrome is a recently established adult-onset autoinflammatory disorder caused by somatic mutations in the ubiquitin-activating enzyme 1 (UBA1) gene. The condition predominantly affects men in later stages of life and is characterised by recurrent systemic inflammation, fever, pulmonary involvement, dermatological manifestations, haematological abnormalities, and frequent corticosteroid dependence. Due to its heterogeneous clinical presentation, diagnosis can often be delayed, effectively resulting in significant morbidity and mortality. We report the case of a 78-year-old man who presented with recurrent episodes of high-grade fever, a widespread rash, pulmonary infiltrates, and repeated episodes initially diagnosed as periorbital cellulitis. Despite extensive investigations and multiple courses of antibiotics, no infective source was identified. The patient demonstrated recurrent inflammatory flares that responded to corticosteroids but relapsed during steroid tapering. Over the course of approximately one year, he developed progressive systemic inflammation, constitutional symptoms, pulmonary involvement, and normocytic normochromic anaemia. Following emerging recognition that macrocytosis may not be universally present in VEXAS syndrome, the diagnosis was considered and confirmed by bone marrow examination and genetic testing, demonstrating a pathogenic UBA1b mutation (p.Met41Val, c.121A>G). Unfortunately, the patient deteriorated rapidly and died before the diagnostic results became available. This case highlights the diagnostic challenges associated with VEXAS syndrome, particularly in patients lacking classical haematological features such as macrocytosis. Increased awareness of the expanding phenotypic spectrum of VEXAS syndrome is essential to facilitate earlier diagnosis and timely multidisciplinary management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.